FDA Approves New Bleeding Antidote Andexxa

There is promising news for the more than 4 million patients who take Xarelto® (Riviaroxaban) or Eliquis® (Aixaban) on a daily basis. These blood thinners, while effective, have been shown to cause uncontrolled and sometimes life-threatening bleeding events.  The FDA has finally approved a reversal agent that can stop the anticoagulant effects of Xa inhibitors, in the form…

Xarelto Litigation Update

Plaintiffs from around the nation claim that Bayer’s anticoagulant medication Xarelto was defectively designed and marketed with inadequate warnings about the risk of uncontrolled bleeding. Approved by the FDA in 2011, Xarelto is prescribed to treat blood clots, deep vein thrombosis and pulmonary embolism, and is one of the top-selling blood thinners on the market.…